Administration Route Dependent Bioavailability of Interferon-α and Effect of Bile Salts on the Nasal Absorption
- 1 January 1993
- journal article
- research article
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 19 (10) , 1183-1199
- https://doi.org/10.3109/03639049309063011
Abstract
Administration route dependent bioavailability of recombinant human interferon alpha (IFN-α) and effect of seven bile salts and polyoxyethylene-9-lauryl ether (BL-9) on nasal absorption of IFN-a were studied in rats. IFN-a (1.5 × 10 7 IU/kg) was administered through iv, pv, po and ip routes and AUC of the routes were compared. As a result, it was found that IFN-α is extracted almost completely during its passage through the GI lumen, and is not absorbed from the GI lumen. Moreover, IFN-α sparingly transported through the GI lumen suffers additional extraction by the GI mucosa (57%) and the liver (8%) consecutively and only about 40% of it can reach the systemic circulation. Therefore, a high bioavailability of IFN-a cannot be expected through the oral route even with the aid of absorption enhancers. On the other hand, significant absorption of IFN-α could be attained through the nasal route with some absorption enhancers (1% w/v). Among the enhancers examined, sodium cholate (CH), sodium glycocholate (GC), sodium taurocholate (TC), sodium glycodeoxycholate (GDC), sodium taurodeoxycholate (TDC) and BL-9 increased the nasal bioavailability of IFN-a. However, sodium dehydrocholate (DHC) and sodium deoxycholate (DOC) did not show such effect. Nasal bioavailability of IFN-a was increased up to 32.3 (± 15.5)% by 1% TC. The enhancing effect of TC was significantly (p<0.05) greater than those of CH, DOC, DHC and BL-9. TC and GC seemed to be potential candidates for the nasal absorption enhancers of IFN-α, considering that they are reportedly less toxic than GDC and TDC.Keywords
This publication has 33 references indexed in Scilit:
- Effect of absorption promoters in intranasal administration of human fibroblast interferon as a powder dosage form in rabbits.CHEMICAL & PHARMACEUTICAL BULLETIN, 1989
- Oral administration of human recombinant interferon-α2 in ratsInternational Journal of Pharmaceutics, 1988
- Enzyme immunoassay of human fibroblast interferon after intranasal administration with several excipients in rabbits.CHEMICAL & PHARMACEUTICAL BULLETIN, 1988
- Tolerance and nasal histopathologic effects of long-term, low-dose intranasal recombinant interferon alpha-2A (Roferon-A)Antiviral Research, 1987
- Aminopeptidase activity in homogenates of various absorptive mucosae m the albino rabbit: implications in peptide deliveryInternational Journal of Pharmaceutics, 1986
- Nasal absorption of insulin: enhancement by hydrophobic bile salts.Proceedings of the National Academy of Sciences, 1985
- Pharmacokinetics of Recombinant Leukocyte A Interferon Following Various Routes and Modes of Administration to the DogJournal of Interferon Research, 1985
- Pharmacokinetics of Recombinant Alpha A Interferon Following IV Infusion and Bolus, IM, and PO Administrations to African Green MonkeysJournal of Interferon Research, 1984
- Comparative Intranasal Pharmacokinetics of Interferon Using Two Spray SystemsJournal of Interferon Research, 1983
- Circulating Interferon in Rabbits after Administration of Human Interferon by Different RoutesJournal of General Virology, 1973